CMS projects a 16.5% decline in the enrollment-weighted average MA premium for 2027. But the number covers all plan types and can move because of enrollment distribution. The investment question is which carriers can defend margin while managing Star-bonus exposure heading into AEP.
CMS released its 2027 Medicare Advantage landscape data on September 28, 2026, and the headline number travels fast: the enrollment-weighted average monthly premium across all MA plans is projected to fall from $14.37 in 2026 to $12.00 in 2027. That is a 16.5% decline. The figure comes directly from the CMS press release and covers a specific, carefully defined universe: all Medicare Advantage plans, including plans with prescription drug coverage (MA-PD) and Special Needs Plans (SNPs).
That definition matters. The $12.00 figure is not a statement that every MA member's premium fell, or that the average individual shopping the MA market during AEP will see a 16.5% reduction in their bill. The figure is not the average all-in monthly cost of MA coverage. It is CMS's projected enrollment-weighted MA plan premium and should be evaluated alongside Part B premiums, cost-sharing, maximum out-of-pocket amounts, drug coverage, provider networks, and supplemental benefit design. An enrollment-weighted average can move because plans change premiums, because enrollment is expected to shift among products and markets, or because the mix of available plans changes. CMS's national figure does not identify how much of the projected decline comes from each mechanism. The relevant analytical task is to examine premium, benefit, plan-count, and enrollment changes at the carrier, contract, product, and county level. A $0 MA plan premium can coexist with meaningful differences in Part B premium givebacks, deductibles, copays, maximum out-of-pocket limits, networks, formulary rules, and supplemental-benefit allowances.
Market reporting indicates a more mixed premium environment than the headline suggests. [verify: Healthcare Dive and industry analyst reporting on 2027 MA plan landscape indicates fewer $0-premium MA-PD plans available and some MA-PD premiums rising; confirm against published landscape coverage from late September or early October 2026.] The CMS premium average should therefore be read alongside carrier-level changes in benefit allowance amounts, Part B givebacks, cost sharing, maximum out-of-pocket limits, network breadth, and product availability, not premium alone. A Leerink Partners analysis of Medicare Plan Finder, reported by Healthcare Dive, found that major MA carriers reduced selected 2027 benefits, including dental allowances and Part B premium givebacks, as they prioritized margin recovery.
CMS reports that the total number of available MA plans nationally is expected to remain roughly stable, declining modestly from 5,553 in 2026 to approximately 5,532 in 2027. That plan-count figure is flat in aggregate, but the composition within that count matters more than the total. Plan design changes, including adjustments to cost-sharing, network scope, and supplemental benefit packages, are where carriers are making margin-protective decisions that do not necessarily register in a simple premium average.
CMS also notes that approximately eight in ten MA beneficiaries will be able to remain in their current plan with the same or a lower premium in 2027. That is broadly reassuring on premium continuity for many existing members. For investors, the operative questions are what happens among the remaining beneficiaries: how many face higher premiums, product discontinuations, network or benefit changes, or voluntary switching opportunities, and where that enrollment moves.
Understanding what this AEP means for 2028 carrier economics requires holding a clear sequencing model.
First: 2027 plan premium and benefit design set the parameters for enrollment during AEP, which runs from October 15 through December 7, 2026. Where enrollment grows matters as much as whether it grows. Growth concentrated in SNPs or other high-acuity product lines carries different utilization and cost profiles than growth in standard MA-PD plans. Growth in markets where a carrier's medical cost structure is already under pressure compounds that exposure.
Second: Star Ratings are one of the most consequential inputs to 2028 competitive positioning, especially for contracts near the 4.0-star quality-bonus threshold. CMS is expected to post 2027 Star Ratings on or around October 8, 2026. [verify: confirm 2027 Star Ratings release date from CMS; historical pattern is early October release ahead of AEP.] Contracts that achieve a rating of 4.0 stars or higher qualify for the quality bonus payment (QBP). For eligible contracts, a quality bonus payment raises the applicable benchmark. Together with the contract's bid and rebate percentage, that can expand the resources available for 2028 benefits, premium reduction, cost-sharing, and margin support. A contract that misses 4.0 stars does not receive the quality-bonus benchmark enhancement available to qualifying competitors. That can narrow the resources available for 2028 benefit design, premium reduction, cost-sharing, or margin support, depending on the county benchmark, bid, rebate percentage, enrollment, medical-cost trend, and benefit strategy.
The sequencing is direct: 2027 Star Ratings determine 2028 quality bonus eligibility. 2027 AEP enrollment affects 2027 revenue and medical cost exposure, but 2027 enrollment volume does not itself determine 2028 bonus status. Conflating these two sequences leads to analytical error. The carrier risk heading into 2028 is not simply that high enrollment creates cost pressure. Enrollment growth in a contract that misses the 4.0-star threshold requires more disciplined pricing, risk-adjustment execution, benefit design, network management, and medical-cost control. Without the quality-bonus benchmark enhancement available to 4.0-star competitors, the contract's economics depend more heavily on member acuity, coding and risk-adjustment performance, utilization trend, provider contracts, and benefit design.
Third: 2028 bid economics are set against whatever benchmark and bonus position a carrier holds after the 2027 Star Ratings cycle. Contracts operating near the 4.0-star threshold face a binary inflection. Above 4.0 stars, a qualifying contract has the QBP-related benchmark advantage available to incorporate into its 2028 bid. Below 4.0 stars, the contract must compete without that specific payment advantage. The practical effect varies materially by county and contract economics.
The margin backdrop is carrier-specific, not uniform. Carrier disclosures reflect differing exposure to medical-cost trend, pricing adequacy, risk-adjustment execution, benefit changes, product exits, and network strategy. Investors should compare each carrier's own segment-level medical-cost metrics, outlook, MA membership trajectory, and 2027 product changes rather than treating "elevated MA MLRs" as a uniform sector condition.
Centene reported an 89.5% Medicare health-benefits ratio in the second quarter of 2026, down from 90.9% a year earlier, underscoring that margin restoration is carrier- and segment-specific rather than a single industry-wide story.
In that context, the decisions embedded in 2027 plan design are not primarily about competing for share at any cost. They are about protecting the margin position and Star-bonus status that determine 2028 competitive capacity.
The investor-relevant questions for this AEP cycle are specific. Which carriers reduced premiums in broad MA-PD products versus SNP lines, and what does that imply about expected enrollment mix? Which counties are losing $0-premium options or experiencing plan exits, and which carriers are positioned to absorb switching members? Which contracts sit near the 4.0-star threshold, where 2028 QBP eligibility may change? Are lower premiums paired with narrower networks, higher maximum out-of-pocket limits, smaller Part B premium givebacks, or lower supplemental-benefit allowances? And can carriers absorb enrollment movement without weakening provider access, member experience, care management, or future Star-measure performance?
On enrollment scale: CMS estimates 34 million MA enrollees in 2027, representing approximately 47.4% of all Medicare beneficiaries. CMS notes explicitly that plan enrollment projections have historically understated actual enrollment, so the realized figure may be higher. At roughly 47% Medicare penetration, MA's aggregate growth rate and mix are increasingly important to distinguish from headline enrollment totals. The 2027 AEP is likely to be shaped by where share moves, which products attract it, and whether that growth improves or dilutes carrier economics.
CMS says benefits such as hearing, dental, and vision will remain broadly available in 2027. That is an availability statement, not a statement that benefit generosity is unchanged. Healthcare Dive reported that a Leerink Partners analysis of Medicare Plan Finder found selected reductions among large carriers, including lower dental allowances and smaller Part B premium givebacks.
The investment question is therefore not simply whether a carrier still offers dental, vision, or hearing. It is whether benefit-value reductions are concentrated in products, counties, or contracts where the carrier can preserve retention and growth without worsening complaints, disenrollment, utilization, or future Star-measure performance.
The $12 monthly premium figure is real, and the 16.5% change is mathematically correct. It does not reveal whether a carrier is buying growth with richer benefits, preserving membership through targeted pricing, retreating from unprofitable counties, or narrowing benefit value while keeping a low premium headline. Nor does it identify which contracts will enter 2028 with quality-bonus eligibility. That analysis requires contract- and market-level work: premium, benefit, network, enrollment, medical-cost trend, and Star Rating data viewed together, not an aggregate CMS figure in isolation.
This is analysis, not investment advice. Continuum does not make recommendations to buy or sell securities.
Discover how Addie helps health systems, post-acute providers, and payers improve throughput, reduce avoidable days, and deliver better transitions of care.
Get Started
